Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 3/2007

01-03-2007 | Original Article

Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma

Authors: M. Reni, S. Cereda, E. Bonetto, M. G. Viganò, P. Passoni, A. Zerbi, G. Balzano, R. Nicoletti, C. Staudacher, V. Di Carlo

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2007

Login to get access

Abstract

Background

PEFG regimen (cisplatin and epirubicin 40 mg/m2 day 1, gemcitabine 600 mg/m2 days 1 and 8, 5-fluorouracil (FU) 200 mg/m2/day continuous infusion) significantly improved the outcome of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine in a previous phase III trial. This regimen was subsequently modified in a dose-finding study by increasing dose intensity of cisplatin and epirubicin (both at 30 mg/m2 every 14 days) and of gemcitabine (at 800 mg/m2 every 14 days). Results of a consecutive series treated by dose-intense PEFG regimen are herewith reported.

Material and methods

Dose-intense PEFG was administered to chemotherapy-naive patients with stages III–IV PA, < 75 years, performance status (PS) > 50, till progressive disease or for a maximum of 6 months.

Results

Between January 2004 and June 2005, 49 (31 or 63% metastatic) patients, median age 62 years, median PS 80, were treated with dose-intense PEFG. Partial response and stable disease was observed in 24 (49%) and 16 (33%) patients, respectively; 31 patients were progression-free at 6 months (PFS-6 = 63%). Median survival was 10.5 months and 1-year overall survival (OS) was 48% (95% confidence interval: 33–61%). Main grade 3–4 toxicity was: neutropenia in 26% of patients, stomatitis and fatigue in 8%, anaemia, diarrhoea, nausea/vomit in 6%, febrile neutropenia and thrombocytopaenia in 4%, hand-foot syndrome in 2%.

Conclusion

When compared with 84 patients treated by classical PEFG at the same institution, dose-intense PEFG was not inferior in terms of PFS-6 (63 versus 57%), 1-year OS (48 versus 42%) and response rate (49 versus 49%); it allowed to increase dose intensity for gemcitabine by 32%, for cisplatin and epirubicin by 36% (FU reduced by 3%), to significantly reduce grade 3–4 hematological toxicity (neutropenia: 26 versus 86%; P < 0.00001; thrombocytopaenia: 4 versus 58%; P < 0.00001) and to reduce by one-third the number of outpatient accesses. The new PEFG schedule appears more suitable for clinical use and should be preferred as a basis for further development of therapeutic strategies against pancreatic cancer.
Literature
1.
Moore MJ, Goldstein D, Hamm J et al (2005) Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trial Group (NCIC-CTG). In: Proceedings of the 2005 Gastrointestinal Cancers Symposium, Hollywood, FL, USA, 3: abstr 77, 27–29 Jan 2005
2.
Cunningham D, Chau I, Stocken D et al (2005) Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer 3:12 (abstr PS 11)
3.
Reni M, Cordio S, Milandri C et al (2005) Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a phase III trial. Lancet Oncol 6:369–376PubMedCrossRef
4.
Reni M, Passoni P, Panucci MG et al (2001) Definitive results of a phase II trial of PEF-G (cisplatin, epirubicin, 5-fluorouracil continuous infusion, gemcitabine) in stage IV pancreatic adenocarcinoma. J Clin Oncol 19:2679–2686PubMed
5.
Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMed
6.
Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270–3275PubMedCrossRef
7.
Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A et al (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3296–3302PubMedCrossRef
8.
Rocha Lima CMS, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA et al (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776–3783PubMedCrossRef
9.
Bramhall SR, Schultz J, Nemunaitis J, Brown PD, Baillet M, Buckels JAC (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161–167PubMedCrossRef
10.
Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA, for the Marimastat Pancreatic Cancer Study Group (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19:3477–3455
11.
Heinemann V, Quietzsch D, Gieseler F, Gonnermann N, Schonekas H, Rost A, et al. (2003) A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 22 (abstr 1003)
12.
Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A et al (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438PubMedCrossRef
13.
Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taı¨eb J, Faroux R, Lepere C, de Gramont A (2005) Gemcitabine in combination with Oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509–3516PubMedCrossRef
14.
O’Reilly EM, Abou-Alfa GK, Letorneau R, Harker WG, Modiano M, Hurwitz H et al (2004) A randomized phase III trial of DX-8951f (exatecan mesylate) and gemcitabine vs. gemcitabine alone in advanced pancreatic cancer. Proc Am Soc Clin Oncol 23 (abstr 4006)
15.
Oettle H, Richards DA, Ramanathan R, Van Laethem JL, Peeters M, Fuchs M et al (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16:1639–1645PubMedCrossRef
16.
Cheverton P, Friess H, Andras C et al (2004) Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 23:314s (abstr 4005)
17.
Dell’Oro S, Reni M, Bonetto E et al (2004) Intensified PEFG regimen in stage III-IV pancreatic adenocarcinoma. Ann Oncol 15:242 (abstr 919)
18.
Therasse P, Arbuck SG, Eisenhaur EA, Wanders J, Kaplan RS, Rubinstein L et al (2004) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216CrossRef
19.
Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH (1990) Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8:147–159PubMed
20.
Reni M, Passoni P, Bonetto E et al (2005) Final results of a prospective trial of a PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma. Oncology 68:239–245PubMedCrossRef
21.
Topham C, Glees J, Coombs R et al (1993) Comparison of single agent epirubicin and 5-FU/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas. Oncology 50:78–83PubMedCrossRef
22.
Wils JA, Bleiberg H, Blijham G et al (1985) Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer 21:191–194CrossRef
23.
Wils JA, Kok T, Wagener DJ et al (1993) Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 29A:203–204PubMedCrossRef
24.
Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T et al (2002) Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 20:3130–3136PubMedCrossRef
25.
Hidalgo M, Castellano D, Paz-Ares L et al (1999) Phase II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17:585–592PubMed
26.
Rothman H, Cantrell JE, Lokich J et al (1991) Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic adenocarcinoma: a Mid-Atlantic Oncology Program study. Cancer 68:264–268PubMedCrossRef
27.
Nicolson M, Webb A, Cunningham D et al (1995) Cisplatin and protracted venous infusion 5-fluorouracil (CF)––good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann Oncol 6:801–804PubMed
28.
Rougier P, Zarba JJ, Ducreux M et al (1993) Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 4:333–336PubMed
29.
Scheitauer W, Kornek GV, Raderer M et al (1999) Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Br J Cancer 80:1797–1802CrossRef
30.
Heinemann V, Wilke H, Mergenthaler H-G et al (2000) Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11:1399–1403PubMedCrossRef
31.
Ducreux M, Rougier P, Pignon JP, Douillard JY, Seitz JF, Bugat R et al (2002) A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13:1185–1191PubMedCrossRef
32.
Evans TRJ, Lofts FJ, Mensi JL et al (1996) A phase II study of continuous infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 73:1260–1264PubMed
33.
El-Rayes BF, Zalupski MM, Shields AF et al (2003) Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol 21:2920–2925PubMedCrossRef
34.
Reni M, Bonetto E, Cordio S, Passoni P, Milandri C, Cereda S, et al. (2006) Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. Pancreatology (in press)
Metadata
Title
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma
Authors
M. Reni
S. Cereda
E. Bonetto
M. G. Viganò
P. Passoni
A. Zerbi
G. Balzano
R. Nicoletti
C. Staudacher
V. Di Carlo
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 3/2007
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-006-0277-7

Other articles of this Issue 3/2007

Cancer Chemotherapy and Pharmacology 3/2007 Go to the issue

Clinical Trial Report

TEXAS (Taxotere® EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC

Original Article

Reproductive toxicity evaluation of a new camptothecin anticancer agent, CKD-602, in pregnant/lactating female rats and their offspring

Original Article

Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)

Original Article

Adsorption of irinotecan onto oral adsorbent AST-120 (KremezinTM) for preventing delayed diarrhea

Original Article

Intraoperative versus postoperative electrochemotherapy in high grade soft tissue sarcomas: a preliminary study in a spontaneous feline model

Original Article

A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits